Akebia Therapeutics Inc’s recent filing unveils that its SVP, CFO, CBO & Treasurer Ostrowski Erik unloaded Company’s shares for reported $0.15 million on Jun 30 ’25. In the deal valued at $3.67 per share,41,314 shares were sold. As a result of this transaction, Ostrowski Erik now holds 503,586 shares worth roughly $1.89 million.
Then, Ostrowski Erik bought 41,314 shares, generating $151,622 in total proceeds.
Before that, Malabre Richard C sold 15,000 shares. Akebia Therapeutics Inc shares valued at $60,150 were divested by the SVP, Chief Accounting Officer at a price of $4.01 per share. As a result of the transaction, Malabre Richard C now holds 266,914 shares, worth roughly $1.0 million.
A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Jefferies began covering AKBA with “Buy” recommendation on April 01, 2025.
Price Performance Review of AKBA
On Monday, Akebia Therapeutics Inc [NASDAQ:AKBA] saw its stock jump 1.08% to $3.76. Over the last five days, the stock has gained 4.74%. Akebia Therapeutics Inc shares have risen nearly 172.46% since the year began. Nevertheless, the stocks have risen 97.89% over the past one year.
How much short interest is there in Akebia Therapeutics Inc?
A steep rise in short interest was recorded in Akebia Therapeutics Inc stocks on 2025-07-15, growing by 6.87 million shares to a total of 25.37 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 18.5 million shares. There was a rise of 27.09%, which implies that there is a positive sentiment for the stock.
